Huasaiboman Medical Cell Biology
Qingdao Shi
About Huasaiboman Medical Cell Biology
Warseeberman is a cell therapy solution provider, focusing on new cell therapy technologies, based on clinical research, and dedicated to the development of immune cell drug products for the treatment of solid tumors and stem cell therapy products for the treatment of degenerative diseases. The company aims at the cutting-edge technology of tumor immunotherapy, focuses on the development of tumor infiltrating lymphocyte (TIL) drugs for solid tumors, and cooperates with many hospitals to establish a solid tumor and clinical transformation research institute, dedicated to bringing life to solid tumor patients Hope.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2023)
- Website: sino-cellbiomed.com
- Phone: +86 400-6786-208
Industries & Categories
Biotechnology, Life Science, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/huasaiboman-medical-cell-biology-2441692 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.